1. Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1?
- Author
-
Filippo Vairo, Leuridan Cavalcante Torres, Ida Vanessa Doederlein Schwartz, and Marina Cadena da Matta
- Subjects
Adult ,Male ,0301 basic medicine ,Chemokine ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Gastroenterology ,Proinflammatory cytokine ,Immune tolerance ,Young Adult ,03 medical and health sciences ,Immune system ,Internal medicine ,Immune Tolerance ,Humans ,Medicine ,Enzyme Replacement Therapy ,Platelet ,Molecular Biology ,Gaucher Disease ,biology ,business.industry ,Cell Biology ,Hematology ,Enzyme replacement therapy ,Middle Aged ,030104 developmental biology ,Cytokine ,Immunology ,biology.protein ,Cytokines ,Glucosylceramidase ,Molecular Medicine ,Female ,Tumor necrosis factor alpha ,Chemokines ,business ,Brazil - Abstract
Among the lysosomal storage disorders, Gaucher disease (GD) features some of the most striking alterations in the immune system, including increased levels of cytokines and chemokines. Although studies have demonstrated the efficacy of enzyme replacement therapy (ERT) for GD, the ideal dosage remains controversial. In this study, we report differences in levels of cytokines (IL-6, TNF-a, and IFN-y) and chemokines (IL-8, IP-10, and MCP-1) in patients with GD type 1 treated with different ERT dosages and treatment durations. Patients were recruited from two ERT centers in Brazil and divided into two groups according to treatment facility. Comparison between groups showed that patients in group 1 had received ERT for longer (p=0.0078) and at higher doses (p=0.0002) than those in group 2. Patients in group 1 exhibited decreased levels of IL-6 (p=0.0006), TNF-α (p
- Published
- 2018
- Full Text
- View/download PDF